Ftse Mib
38.630,54
1,66%
DAX
22.986,82
2,01%
S&P 500
5.638,94
2,13%
NASDAQ
17.754,09
2,61%
Bitcoin
84.300,34
4,03%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Acadia Pharmaceuticals Inc (ACAD) Acadia Pharmaceuticals Inc (ACAD) Notizie

ACAD

Acadia Pharmaceuticals (ACAD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACAD
DataOraFonteTitoloSimboloCompagnia
07/03/202500:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
06/03/202518:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
03/03/202515:05Business WireAcadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 StudyNASDAQ:ACADAcadia Pharmaceuticals Inc
27/02/202523:26Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACADAcadia Pharmaceuticals Inc
27/02/202522:05Business WireAcadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
26/02/202522:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACADAcadia Pharmaceuticals Inc
26/02/202522:05Business WireAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
14/02/202522:05Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACADAcadia Pharmaceuticals Inc
14/02/202515:00Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ACADAcadia Pharmaceuticals Inc
12/02/202522:05Business WireAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025NASDAQ:ACADAcadia Pharmaceuticals Inc
14/01/202515:05Business WireAcadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
30/12/202423:37PR Newswire (US)Acadia Pharmaceuticals Set to Join S&P SmallCap 600NASDAQ:ACADAcadia Pharmaceuticals Inc
19/12/202422:05Business WireAcadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025NASDAQ:ACADAcadia Pharmaceuticals Inc
11/12/202422:05Business WireAcadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 MillionNASDAQ:ACADAcadia Pharmaceuticals Inc
11/12/202400:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACADAcadia Pharmaceuticals Inc
09/12/202415:00Business WireAcadia Pharmaceuticals Appoints Thomas Garner Chief Commercial OfficerNASDAQ:ACADAcadia Pharmaceuticals Inc
26/11/202422:05Business WireAcadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711NASDAQ:ACADAcadia Pharmaceuticals Inc
21/11/202422:05Business WireAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesNASDAQ:ACADAcadia Pharmaceuticals Inc
14/11/202412:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ACADAcadia Pharmaceuticals Inc
06/11/202422:05Business WireAcadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
05/11/202422:05Business WireAcadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 MillionNASDAQ:ACADAcadia Pharmaceuticals Inc
18/10/202400:41Business WireAcadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024NASDAQ:ACADAcadia Pharmaceuticals Inc
16/10/202422:07Business WireAcadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett SyndromeNASDAQ:ACADAcadia Pharmaceuticals Inc
16/10/202422:07Business WireAcadia Pharmaceuticals annonce l’approbation de DAYBUE™ (trofinétide) par Santé Canada pour le traitement du syndrome de RettNASDAQ:ACADAcadia Pharmaceuticals Inc
23/09/202423:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACADAcadia Pharmaceuticals Inc
23/09/202422:15Business WireCatherine Owen Adams Succeeds Steve Davis as CEO of Acadia PharmaceuticalsNASDAQ:ACADAcadia Pharmaceuticals Inc
20/08/202422:39Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ACADAcadia Pharmaceuticals Inc
14/08/202414:04Business WireRyan Reynolds Announces More to Parkinson’s® CampaignNASDAQ:ACADAcadia Pharmaceuticals Inc
07/08/202422:30Business WireAcadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:ACADAcadia Pharmaceuticals Inc
06/08/202422:05Business WireAcadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating OverviewNASDAQ:ACADAcadia Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACAD

La tua Cronologia

BTRX
APEUSD
ApeCoin
COIN
COREEEETH
cVault.finance
BOV
VIVT3Q
TELEF BRASIL ON
EU
WORLD
Franklin Templeton ICAV
UNSW3
KARMAETH
Karma
BOV
BTML11
Barra Malls Fundo De Inv...
BOV
ITUB3Q
ITAU UNIBANCO ON
BOV
GMAT3M
Grupo Mateus ON
NASDAQ
ABODTXX
Morgan Stanley Finance L...
USOTC
AXIIF
Alexium (PK)
COIN
NAMEUR
LATK
HTKBTC
Hightekers Token
NASDAQ
SEEM
SEI Select Emerging Mark...
GATE
KASUSDT
Kaspa
LATK
LSCBTC
LigerStar Coin
NASDAQ
TROO
TROOPS
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci